Skip to main content

Drug Interactions between bacitracin and kanamycin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

kanamycin bacitracin

Applies to: kanamycin and bacitracin

GENERALLY AVOID: The combination of a polypeptide antibiotic and an aminoglycoside may increase the risk of neurotoxicity, respiratory paralysis, and renal dysfunction. The mechanism of this interaction is not known, but may involve additive or synergistic effects.

MANAGEMENT: This combination should be avoided concurrently or sequentially. If coadministration is medically necessary, patients should be closely monitored for development of toxicity, including renal function tests, respiratory function, and vestibular and audiometric tests.

References

  1. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE "Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy." Ann Intern Med 72 (1970): 857-68
  2. "Product Information. Amikin (amikacin)." Bristol-Myers Squibb PROD (2002):
  3. "Product Information. Garamycin (gentamicin)." Schering-Plough Corporation PROD (2007):
  4. "Product Information. Nebcin (tobramycin)." Lilly, Eli and Company PROD (2001):
  5. Lee C, de Silva AJ "Interaction of neuromuscular blocking effects of neomycin and polymyxin B." Anesthesiology 50 (1979): 218-20
  6. Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL "Reversible respiratory paralysis associated with polymyxin therapy." Ann Intern Med 68 (1968): 318-27
  7. "Product Information. Arikayce (amikacin liposome)." Insmed Incorporated (2018):
View all 7 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer